Dianthus Therapeutics (DNTH) Other Accumulated Expenses (2022 - 2023)
Dianthus Therapeutics' (DNTH) quarterly Other Accumulated Expenses came in at $279000.0 in Q2 2023, up 24.55% quarter-over-quarter from $224000.0 in Q1 2023.
Dianthus Therapeutics (DNTH) Other Accumulated Expenses (2022 - 2023) Analysis & Trends
Dianthus Therapeutics' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $279000.0 for Q2 2023.
- On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $279000.0 in Q2 2023; TTM through Jun 2023 was $279000.0, a N/A change from a year earlier, with the FY2022 full-year figure at $364000.0, changed N/A from the prior year.
- Other Accumulated Expenses rose to $279000.0 in Q2 2023 per DNTH's latest filing, from $224000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $364000.0 in Q4 2022 and bottomed at $224000.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Dianthus Therapeutics | 3.37 Bn | 2.97 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 279,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 364,000.00 |